Diabetes drugs ‘reduce MS biomarkers’

[MSUK]

The diabetes drug Actos benefited multiple sclerosis patients with metabolic syndrome in a small trial, a new study has found. Researchers followed 50 MS patients with obesity who were taking metformin or pioglitazone, or who were not treated with either agent; those receiving the active drugs showed reductions in several biomarker measures including MRI lesion burden compared with the untreated controls, according to a report published on Monday in JAMA Neurology...Read more - http://www.ms-uk.org/MSnews